Cargando…
Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES
Autores principales: | Ferraccioli, Gianfranco, Tolusso, Barbara, Fedele, Anna Laura, Gremese, Elisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823584/ https://www.ncbi.nlm.nih.gov/pubmed/27099779 http://dx.doi.org/10.1136/rmdopen-2016-000263 |
Ejemplares similares
-
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
por: Ferraccioli, Gianfranco, et al.
Publicado: (2016) -
The forgotten key players in rheumatoid arthritis: IL-8 and IL-17 – Unmet needs and therapeutic perspectives
por: Gremese, Elisa, et al.
Publicado: (2023) -
Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression
por: Bosello, Silvia, et al.
Publicado: (2011) -
Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission
por: Alivernini, Stefano, et al.
Publicado: (2016) -
Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis
por: Fedele, Anna Laura, et al.
Publicado: (2014)